ArticleInternational journal of rheumatic diseases2026
Interstitial Lung Disease in Rheumatoid Arthritis: Incidence and Outcomes in Western Australia.
Article in International journal of rheumatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo determine the incidence, risk factors for, and mortality from interstitial lung disease (ILD) in patients with Rheumatoid Arthritis (RA) in Western Australia (WA).
methodsA retrospective statewide cohort study of ILD in patients with RA (n = 5971) and age/sex matched controls (n = 20 830) hospitalized between 1985 and 2014. ILD was identified based on validated algorithms. ILD incidence (IR) per 1000 person-years (PY), odds ratio (OR) for risk factors and respiratory complications, and mortality rate (MR) per 1000 PY were estimated with 95% confidence intervals (CI).
resultsThe IR of ILD in patients with RA (RAILD+) was increased (IR ratio 8.02, CI 6.28-10.32) and stable over 30 years. Age (OR 1.02, CI 1.01-1.03), smoking (OR 1.97, CI 1.48-2.63), and scleritis (OR 3.84, CI 1.86-7.94) were independent risk factors for ILD. Pulmonary infections, oxygen dependence, and lung cancer occurred as frequently in RAILD+ and CoILD+ but at higher rates than in participants without ILD in each group. MR for RAILD+ patients was higher than for RA patients not developing ILD (99.9 vs. 50.8; p < 0.01), but lower than for CoILD+ (166.3 vs. 99.9, p < 0.01).
conclusionThe incidence of ILD among patients with RA was stably increased over time. ILD increased respiratory morbidity and mortality in both RA and controls. Smoking cessation and early detection could reduce the risk and severity of ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.